R-PR's Menorest Approved In France
Rhone-Poulenc Rorer's Menorest (transdermal 17-beta estradiol) has been approved in France for use in the treatment of postmenopausal symptoms such as hot flushes, night sweats and vaginal dryness. The company expects to launch the product in France through its French affiliate Theraplix "during the first half of 1995."
Menorest was originally developed by Noven Pharmaceuticals, a company which specializes in the development and commercialization of transdermal drug delivery systems. This is the second approval for the hormone replacement product - Menorest was first approved in Finland on December 29, 1994, for the treatment of menopausal symptoms and the prevention of osteoporosis.
The patch has been approved in four dosage strengths - 37.5mcg, 50mcg, 75mcg and 100mcg - and each patch provides hormone replacement continuously for three to four days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze